The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Open accessAbstract
Background [177 Lu]Lu-PSMA-617 (177 Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of 177 Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer.Methods In this phase 3, randomised, controlled trial conducted at 74 sites across Europe and North America, taxane-naive patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who had progressed once on a previous ARPI were randomly allocated (1:1) to open-label, intravenous 177 Lu-PSMA-617 at a dosage of 7·4 GBq (200 mCi) ± 10% once every 6 weeks for six cycles, or a change of ARPI (to abiraterone or enzalutamide, administered orally on a continuous basis per product labelling). Crossover from ARPI change to 177 Lu-PSMA-617 was allowed after centrally confirmed radiographic progression. The primary endpoint was radiographic progression-free survival, defined as the time from randomisation until radiographic progression or death, assessed in the intention-to-treat population. Safety was a secondary endpoint. This study is registered with ClinicalTrials.gov (NCT04689828) and is ongoing. In this primary report of the study, we present primary (first data cutoff) and updated (third data cutoff) analyses of radiographic progression-free survival; all other data are based on the third data cutoff.Findings Overall, of the 585 patients screened, 468 met all eligibility criteria and were randomly allocated between June 15, 2021 and Oct 7, 2022 to receive 177 Lu-PSMA-617 (234 [50%] patients) or ARPI change (234 [50%]). Baseline characteristics were mostly similar between groups; median number of 177 Lu-PSMA-617 cycles was 6·0 (IQR 4·0-6·0). Of patients assigned to ARPI change, 134 (57%) crossed over to receive 177 Lu-PSMA-617. In the primary analysis (median time from randomisation to first data cutoff 7·26 months [IQR 3·38-10·55]), the median radiographic progression-free survival was 9·30 months (95% CI 6·77-not estimable) in the 177 Lu-PSMA-617 group versus 5·55 months (4·04-5·95) in the ARPI change group (hazard ratio [HR] 0·41 [95% CI 0·29-0·56]; p<0·0001). In the updated analysis at time of the third data cutoff (median time from randomisation to third data cutoff 24·11 months [IQR 20·24-27·40]), median radiographic progression-free survival was 11·60 months (95% CI 9·30-14·19) in the 177 Lu-PSMA-617 group versus 5·59 months (4·21-5·95) in the ARPI change group (HR 0·49 [95% CI 0·39-0·61]). The incidence of grade 3-5 adverse events was lower in the 177 Lu-PSMA-617 group (at least one event in 81 [36%] of 227 patients; four [2%] grade 5 [none treatment related]) than the ARPI change group (112 [48%] of 232; five [2%] grade 5 [one treatment related]).Interpretation 177 Lu-PSMA-617 prolonged radiographic progression-free survival relative to ARPI change, with a favourable safety profile. For patients with PSMA-positive metastatic castration-resistant prostate cancer who are being considered for a change of ARPI after progression on a previous ARPI, 177 Lu-PSMA-617 may be an effective treatment alternative.Funding Novartis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The findings in the third data cutoff point thus far showed that those in the experimental group exhibited a statistically significant improvement in rPFS compared to the ARPI change group (median 11.6 months vs 5.59 months; HR:0.49).”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Preliminary safety analysis indicated that 177Lu-PSMA- 617 was generally well-tolerated with lower incidence of grade 3–5 adverse events as compared to control group, while OS data is still not fully mature”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationLutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Self-citationOlaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citationScher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citationInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
(1997) · PubMed · Cited by 1,541
Hofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170
Defining the clinically important difference in pain outcome measures
Farrar, J. T., Portenoy, R. K., Berlin, J. A., Kinman, J. L., & Strom, B. L. (2000) · Pain · doi:10.1016/s0304-3959(00)00339-0 · Cited by 1,071
Research works printed but not linked: 1
- Raychaudhuri, 2024, Genomic correlates of prostate-specific membrane antigen expression and response to 177Lu-PSMA-617: a retrospective multicenter cohort study, JCO Precis Oncol, 8
Cited by
Sorted by citations
Items 101–200 of 362
Abdlkadir, A. S., Al-Adhami, D. A., Moghrabi, S., Sathekge, M. M., Kreissl, M. C., Estrada-Lobato, E., Shi, H., & Al‐Ibraheem, A. (2026) · BMC Cancer · doi:10.1186/s12885-026-15900-y · Cited by 3
Zarka, J. G., Juthani, R., Sartor, O., Muniz, M., Kase, A. M., Riaz, I. B., Naqvi, A., Heath, E., Orme, J. J., Scharf, Z., et al. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102552 · Cited by 3
Self-citationRadiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts
Deandreis, D., Jacene, H. A., Therasse, P., André, F., Barlési, F., Haigis, K. M., Fizazi, K. S., & Choueiri, T. K. (2026) · Oncology and Therapy · doi:10.1007/s40487-026-00432-z · Cited by 3
Self-citationBauckneht, M., Evangelista, L., Sofia, L., Maccauro, M., Filice, A., Rimini, M. L. D., Caffo, O., Messina, C., Maruzzo, M., Pinterpe, G., et al. (2026) · Clinical and Translational Imaging · doi:10.1007/s40336-026-00766-8 · Cited by 3
Arafa, A. T., Boytim, E., Ludwig, M., Kollitz, L., Yang, T., Storey, K. M., Bloom, S. H., Jha, G., Okazaki, I. J., Ryan, C. J., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102764 · Cited by 3
Shore, N. D., Fizazi, K. S., Schweizer, M. T., Castro, E., Azad, A. A., George, D. J., da Trindade, K. M., Zeng, H., Shrivastava, N., Tonkovyd, S., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2667441 · Cited by 3
Self-citationChrenková, E., Spurná, R., Holá, K., Vrbková, J., Knillová, J., Levková, M., Študentová, H., & Bouchal, J. (2025) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2025.02.006 · Cited by 3
Self-citationHolzgreve, A., Unterrainer, L. M., Tiling, M., Mansour, N., Spitzweg, C., Brendel, M., Ricke, J., Unterrainer, M., Kunz, W. G., & Mehrens, D. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269416 · Cited by 3
Fluorescent PSMA-Targeted Radiotheranostic Compounds for Multiscale Imaging
Simpson, G. G., Quintana, J. M., Carrothers, J. E., Jiang, F., Walker, S. A., Cho, C., Weissleder, R., Miller, M. A., & Ng, T. S. C. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00139 · Cited by 3
Fiorica, F., Candela, M. V., Sava, T., Salgarello, M., Giuliani, J., Singh, N., Franceschetto, A., Grigolato, D., Durante, E., Palesandro, E., et al. (2025) · Cancers · doi:10.3390/cancers17132247 · Cited by 3
Izumi, K., Matsumoto, R., Ito, Y., Hoshi, S., Matsubara, N., Yamasaki, T., Mizowaki, T., Komaru, A., Nomura, S., Hattori, T., et al. (2025) · Cancers · doi:10.3390/cancers17142351 · Cited by 3
Hennes, D. M. Z. B., Weindler, J. J., Babst, C., Perera, M., Murphy, D. G., & Eapen, R. S. (2025) · Current Opinion in Urology · doi:10.1097/mou.0000000000001323 · Cited by 3
Ninatti, G., Al‐Ibraheem, A., Lee, S. T., & Scott, A. M. (2025) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.25.03635-0 · Cited by 4
Schwinger, M., Kalogirou, C., Scheper, V., Däuwel, M., Weber, S., Seitz, A. K., Kübler, H. R., Buck, A. K., Werner, R. A., & Hartrampf, P. E. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07519-1 · Cited by 3
Peláez, I., Lázaro-Quintela, M., Pérez-Fentes, D., Esteban-González, E., Gallardo, E., Álvarez-Fernández, C., Rodríguez, P. Á., Anido, U., Raposeiras, C. A., Castro‐Iglesias, Á., et al. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03850-z · Cited by 2
Lutetium-177 Theranostics and Dosimetry for Neuroendocrine Neoplasms and Prostate Cancer
Wong, K. K., Hu, E. M., Akhavanallaf, A., Dewaraja, Y. K., & Roseland, M. E. (2025) · Seminars in Roentgenology · doi:10.1053/j.ro.2025.04.005 · Cited by 2
Peikin, J. M., Tara, V. K., Johnson, T. R., Barnhart, T. E., Engle, J. W., & Ellison, P. A. (2025) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.112138 · Cited by 2
Howell, J. N., Wilkes, J., Maughan, N. M., Patel, R. B., Barney, B. M., Taunk, N. K., Escorcia, F. E., Johnson, S. B., & Boothe, D. L. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.09.028 · Cited by 2
Giri, V. K., Kolodny, G. M., & Garnick, M. B. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270704 · Cited by 2
Radiotheranostics in Low- and Middle-Income Countries: Challenges, Practice, and Prospects
Lawal, I. O., Ndlovu, H., Kabunda, J., Mokoala, K. M. G., & Sathekge, M. M. (2025) · World Journal of Nuclear Medicine · doi:10.1055/s-0045-1812307 · Cited by 2
French recommendations from the AFU Cancer Committee for prostate cancer: 2025 summary of changes
Ploussard, G., Baboudjian, M., Barret, É., Brureau, L., Dariane, C., Fiard, G., Fromont, G., Mathiéu, R., Olivier, J., Neuzillet, Y., et al. (2025) · The French Journal of Urology · doi:10.1016/j.fjurol.2025.103010 · Cited by 2
Self-citationFifty Shades of PSMA-Avid Rib Lesions: A Comprehensive Review
Shamshirgaran, A., Samadi, M. H., Saeed, M., Harsini, S., Sahafi, P., Divband, G., Mohammadi, G., Ayati, N., Sadeghi, R., Rizzo, A., et al. (2025) · Cancers · doi:10.3390/cancers17213404 · Cited by 2
Schweigert, N., Strewinsky, N., Koehler, D., Lehnert, W., Ekrutt, J., Karimzadeh, A., Klutmann, S., Amsberg, G. V., & Sauer, M. (2025) · Cancers · doi:10.3390/cancers17213515 · Cited by 2
Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer
Adeleke, S. M., Galante, J. R., Wang, Y., Azad, G. A. A., Wan, S., Haroon, A., Bianchini, D., Bomanji, J. B., Hofman, M. S., Young, T. S., et al. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01107-6 · Cited by 2
Alexoff, D., Plöessl, K., Zhao, R., Li, L., Kim, D., Zhu, L., & Kung, H. F. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00400-4 · Cited by 2
Beek, E. T. T., Gerritse, S. L., & Verburg, F. A. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70128 · Cited by 2
Kind, F., Nemer, U., Brüggemann, K., Jilg, C. A., Meyer, P. T., Mix, M., & Freitag, M. T. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02139-z · Cited by 2
Ren, X., Zhang, L., An, R., Song, H., Shi, M., & Wang, Z. (2026) · Biomedicines · doi:10.3390/biomedicines14020482 · Cited by 2
The path forward for T cell engagers in patients with prostate cancer
Subudhi, S. K., Siddiqui, B. A., Zarrabi, K. K., Kelly, W. K., & Drake, C. G. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013905 · Cited by 2
Hao, X., Du, H., Lin, B., Tang, M., Wang, D., Zhang, H., Zhang, Y., Yang, X., & Du, X. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107491 · Cited by 2
Kurkowska, S., Dewaraja, Y. K., Frey, E. C., Brosch-Lenz, J., Sunderland, J. J., & Uribe, C. (2026) · EJNMMI Physics · doi:10.1186/s40658-026-00848-6 · Cited by 2
Ye, D., Zhao, Y., Yang, L., Sun, X., Cao, T., Yuan, M., Qiao, T., Xing, L., & Sun, X. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102545 · Cited by 2
Hoang, T., Bauer, D., Ingham, A., Miranda, I. C., Carter, L. M., Michel, A. L., Gregorio, R. D., Welk, J., Zhong, H., Poirier, J. T., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271302 · Cited by 2
Self-citationWidjaja, L., Hornfeck, J., Siegmund, S. C., Gildehaus, F. J., Delker, A., Schmidt-Hegemann, N.-S., Rowe, S. P., Casuscelli, J., Stief, C., Zacherl, M. J., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271859 · Cited by 2
Evaluation of novel treatments for metastatic castration-resistant prostate cancer
Güner, G., & Arslan, Ç. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2652456 · Cited by 2
Cockcroft, M., Ferguson, T., Meehan, K., & Al‐Ogaili, Z. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07893-4 · Cited by 2
Ayati, N., Papa, N. P., Crumbaker, M., Subramaniam, S., Joshua, A. M., Alipour, R., Iravani, A., Askari, E., Khan, S., Yadav, S., et al. (2026) · Radiology · doi:10.1148/radiol.252672 · Cited by 2
Büttner, T., Hoffmann, C., Essler, M., Gärtner, F., Kreppel, B., Küppers, J., Ritter, M., Fritzsche, L., Marinova, M., & Krausewitz, P. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271077 · Cited by 2
Molecular Drivers of Prostate Cancer Metastasis: Emerging Targets for Precision Therapy
Iweala, E., & Nwokoro, C. P. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251408321 · Cited by 3
Smoragiewicz, M., Bernard-Tessier, A., Linch, M. D., Shen, J., Shore, N. D., Parikh, O., Chi, K. N., Sokolova, A. O., Culine, S., McKean, M. A., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0253 · Cited by 2
Self-citationAdvances in systemic therapies for advanced prostate cancer
Childs, D. S., Hahn, A. W., Ravi, P. K., & Orme, J. J. (2026) · BMJ · doi:10.1136/bmj-2025-085211 · Cited by 2
Al‐Ibraheem, A., Moghrabi, S., Al-Houwari, R. M., Al-Qasem, S. F., Abdulrahman, M., Alzorgan, N., Al-Qatawna, L., Al-Hammouri, Q., Ghanameh, M., Ruzzeh, S., et al. (2026) · BMJ Oncology · doi:10.1136/bmjonc-2026-001073 · Cited by 2
Khan, S., Papa, N. P., Hioki, T., Crumbaker, M., Lee, S.-T., Weickhardt, A. J., Sharma, S., Weir, S., Lückerath, K., Kwan, E. M., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.126.272714 · Cited by 2
Hlongwa, K., Rivombo, P. M., & More, S. S. (2025) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.25.03643-x · Cited by 2
Management of Metastatic Prostate Cancer
Amsberg, G. V., Busenbender, T., Coym, A., Kaune, M., Strewinsky, N., Ekrutt, J., Tilki, D., & Dyshlovoy, S. A. (2025) · Oncology Research and Treatment · doi:10.1159/000546930 · Cited by 3
Sun, J., Yang, J., Guo, J., Xu, B., Tao, L., Zhao, X., Wang, G., Meng, F., & Zhong, Z. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114945 · Cited by 1
Yazgan, S. C., Kayaş, K., Arslan, Ç., Kapar, C., Öztekin, Ş., Ceylan, F., Bölek, H., Elboğa, U., Ateş, Ö., Tural, D., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf213 · Cited by 1
Aijaz, P., Eby, A., Collins, J. N., & Kamran, A. S. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04804-8 · Cited by 1
Bone Scintigraphy in the Era of PSMA PET: Point—Still a Valuable Tool and Not Yet Dead
Holzgreve, A., & Sartor, O. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.25.33724 · Cited by 1
Self-citationDu, D., Khoo, V. S., Huddart, R. A., & Du, Y. (2025) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002078 · Cited by 1
Enei, Y., Yanagisawa, T., Kuruma, H., Okazaki, C., Watanabe, K., Okada, A., Lenzo, N. P., Kimura, T., & Miki, K. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf179 · Cited by 1
Risk-adapted durations of hormone therapy combined with radiotherapy for prostate cancer
Noro, T., Utsumi, T., Ikeda, R., Ishitsuka, N., Suzuki, Y., Iijima, S., Sugizaki, Y., Somoto, T., Oka, R., Endo, T., et al. (2025) · Academia oncology. · doi:10.20935/acadonco8038 · Cited by 1
Bazarbashi, S. N., Abdelmotal, A., Arabi, T. Z., Fallatah, W., Alzannan, N., Elhassan, T. A. M., Aseafan, M., Mahroos, M., AlJishi, M. N., Busbaih, A., et al. (2025) · BMC Urology · doi:10.1186/s12894-025-02019-8 · Cited by 1
Samadi, M. H., Shamshirgaran, A., Sahafi, P., Elahifard, H., Divband, G., Aryana, K., & Askari, E. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102499 · Cited by 1
161Tb-PSMA radioligand therapy in prostate cancer: current evidence and future perspectives
Xiao, L., Zhao, Z., Luo, R., Liu, F., Hu, B., Zhao, P., Yang, X., & Chen, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1743628 · Cited by 2
LASER: A Phase 2 Trial of 177 Lu-PSMA-617 as Systemic Therapy for RCC
Krauthammer, S. H., Xie, W., LaBrecque, N., Arsenault, L., Kabarame, L., Shah, H., Berg, S. A., McGregor, B. A., Serzan, M. T., Xu, W., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271273 · Cited by 1
Self-citationGerke, M. B., Bedmutha, A. S., Marra, A., Liu, Y., Brown, J. T., Nazha, B., Berchuck, J. E., Parikh, R. B., Ahmed, S. S., Ciuro, J. A., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag022 · Cited by 1
Genomic analysis in chemotherapy-naïve prostate cancer prior to PSMA-targeted treatment
Amghar, M., Roscher, M., Rausch, T., Ozgur, H., Bauder‐Wüst, U., Bruchertseifer, F., Morgenstern, A., Benes, V., Kratochwil, C., & Benešová, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1741080 · Cited by 1
The landscape of top 10 global innovative drug targets 2015-2024
Tan, C., Wang, X., Ding, D., & Xu, P. (2026) · The Innovation Medicine · doi:10.59717/j.xinn-med.2026.100199 · Cited by 1
177Lu-PSMA for prostate cancer: progress, challenges and future perspectives
Xi, Z., Ji, S., Zhang, Y., Sun, M.-H., Jia, G., & Jiang, Q. (2026) · Asian Journal of Andrology · doi:10.4103/aja2025103 · Cited by 1
Takahara, K., Takeuchi, A., Saruta, M., Yoshizawa, A., Nukaya, T., Takenaka, M., Ichino, M., & Sasaki, H. (2026) · International Journal of Urology · doi:10.1111/iju.70375 · Cited by 1
Review of radiopharmaceutical therapy in prostate cancer
Miller, S. R., Dewaraja, Y. K., Rowe, S. P., Reichert, Z. R., & Viglianti, B. L. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.111030 · Cited by 2
Huang, Y., Yang, Y., Zhang, Q., & Wang, S. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105278 · Cited by 1
Krylov, V. V., Kochetova, T. Y., & Пронин, А. И. (2026) · Cancer Urology · doi:10.17650/1726-9776-2025-21-4-15-23 · Cited by 1
Timmermans, B. J. R., Privé, B. M., Hofferber, R., Konijnenberg, M. W., Flux, G. D., Heskamp, S., Nagarajah, J., Gear, J. I., Jentzen, W., & Peters, S. M. B. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07832-3 · Cited by 1
Self-citationCould we reduce renal toxicity of [177Lu]Lu-PSMA radioligand therapy with furosemide?
Pop, S. G., Strobel, K., Heimer, J., Baumann, C., Omlin, A. G., Leike, T., Spielhofer, N., Popescu, C. E., Zander, A., & Burger, I. A. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07865-8 · Cited by 1
Ells, Z., Meyer, C. A. L., Kimura, K., Wilhalme, H., Cao, M., Ludwig, V. B., Unterrainer, L. M., Sennung, D., Nabong, R., Felix, C., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271467 · Cited by 1
Wu, J., Li, X., Gu, C., Hua, L., Liu, R., Li, J., Qiu, M., Guo, J., Dong, H., Ji, Z., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02618-3 · Cited by 1
Systemic Treatments of Castration-Resistant Prostate Cancer
Desai, A. N., Fleyshman, M., Lall, N., & Saraiya, B. (2026) · Urologic Clinics of North America · doi:10.1016/j.ucl.2026.02.013 · Cited by 1
Guideline of guidelines: lutetium‐177 PSMA radioligand therapy in advanced prostate cancer
Al-Khanaty, A., Chen, D. J., Walbaum, J., Hennes, D. M. Z. B., Delgado, C., Dinneen, E. P., Eapen, R. S., Hofman, M. S., Azad, A., Murphy, D. G., et al. (2026) · British Journal of Urology · doi:10.1111/bju.70283 · Cited by 2
Sentana‐Lledo, D., Rami, A., Zhong, C., Muniz, M., Xie, W., Tchitchkan, E., Stoltenberg, H., Riaz, I. B., Wolanski, A., Ritzer, J., et al. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01161 · Cited by 1
Cheng, B., Gong, L., Xu, H., Wang, Z., Huang, H., Guan, X., & Wu, P. (2026) · Oncogene · doi:10.1038/s41388-026-03815-8 · Cited by 1
Clinical Applications of Theranostics
Kuten, J., Bodei, L., & Lewis, J. S. (2026) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-032-21415-7_17 · Cited by 1
Somoto, T., Utsumi, T., Ikeda, R., Sugimoto, T., Ishitsuka, N., Kadono, Y., Noro, T., Suzuki, Y., Iijima, S., Sugizaki, Y., et al. (2026) · Cancers · doi:10.3390/cancers18121966 · Cited by 2
Vascotto, I. A., Antonica, F., Roviello, G., Antonuzzo, L., & Giorgi, U. D. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00658 · Cited by 1
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer
Hooper, G., Jo, Y., Nandakumar, V., Gebrael, G., Özay, Z. İ., Ostrowski, M., Hardy, T., Lin, E., Campbell, P., Murdock, E. G., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.20750 · Cited by 2
Fanti, S., Turco, F., TOMBAL, B. F., Walz, J. C., Hofman, M. S., Hadaschik, B. A., Emmett, L., Tilki, D., Pecoraro, G., Salfi, G., et al. (2026) · European Urology · doi:10.1016/j.eururo.2026.06.009 · Cited by 1
Self-citationRust, M., Ventura, D., Backhaus, C., Platte, O., Matheja, B., Schäfers, M., Bögemann, M., Stegger, L., Roll, W., & Rahbar, K. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-08060-5 · Cited by 1
Zhao, L., Li, L., Zhang, T., He, Q., Yan, J., Yang, X., Wang, K., Yang, M., Xu, L., Hu, K., et al. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100030 · Cited by 1
Ponchelle, M., Kulesza, A., Zieliński, M., Cieszykowska, I., Huber, G., Gravel, E., Pruszyński, M., & Doris, E. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127219 · Cited by 1
Are Radiopharmaceutical Therapy Trials Designed to Undertreat?
Bertolet, A. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00796 · Cited by 1
Mubarika, M., Maaz, M., Muhammad, A., Emmama, S., Mazhar, Z., Khalid, M., kumari, J., Alamin, M. H., Ayalew, B. D., Noor, H., et al. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05329-4 · Cited by 1
Senthamizhchelvan, S., Moore, J. A., & Han-Oh, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166339 · Cited by 1
PSMA-RECAP: [177Lu]Lu-PSMA-617 retreatment in metastatic castration-resistant prostate cancer
Bilgin, G. B., Bilgin, C., Packard, A. T., Burkett, B. J., Oztekin, E. S., Thorpe, M. P., Childs, D. S., Muniz, M., Stoff, R., Nikanpour, Y., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1831393 · Cited by 1
Self-citationHadaschik, B. A., & Sartor, O. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.269608 · Cited by 1
Self-citationDose-Dense Docetaxel and Radium-223 in Bone-Dominant Metastatic Castration-Resistant Prostate Cancer
Connell, B., Hwang, C., Folefac, E., Lawlor, C., Koethe, B. C., & Mathew, P. F. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102368 · Cited by 1
Revolutionizing prostate cancer treatment: PSMA-targeted therapy in modern therapeutics
Ricaurte‐Fajardo, A., Corzo, V. M., Ruder, S., Cardoza-Ochoa, D. R., Granados, C., Yadav, D., López-Delgado, D., Fatima, M., Dutruel, S. P., O’Dwyer, E., et al. (2025) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2025.500162 · Cited by 1
Bitar, R. D., Zurita, P., Martiniova, L., Zurita, A. J., & RAVIZZINI, G. C. (2025) · Cancers · doi:10.3390/cancers17101723 · Cited by 1
Race and Outcomes to [177Lu]Lu-PSMA-617 in Advanced Prostate Cancer
Rami, A., Zhong, C., Muniz, M., Xie, W., Khorasanchi, A., Gallagher, J. F., Mohammadi, S., Fein, D. E. C., Voter, A. F., Stoltenberg, H., et al. (2025) · Cancers · doi:10.3390/cancers17121960 · Cited by 1
Targeted alpha therapy in prostate cancer: review of available agents in clinical practice
Ndlovu, H., Lawal, I. O., Kabunda, J., Kaoma, C. A., Mashigoane, K., Knoesen, Z., RAMONAHENG, K., Sibiya, S. M., Mdlophane, A. H., Mdanda, S., et al. (2025) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.25.03642-8 · Cited by 1
See It, Treat It: How Theranostics Is Reshaping Cancer Care and Nuclear Medicine
Amindarolzarbi, A., & Siegel, E. (2025) · Applied Radiology · doi:10.37549/ar-d-0084 · Cited by 1
Kuo, P. H., Poku, E. K., Yamauchi, D. M., Cha, S. H., Parayno, M., Chong, N. E., Nguyen, C. B., Liu, S. T., Chehrazi‐Raffle, A., Tripathi, A., et al. (2025) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.125.270053 · Cited by 1
Evangelista, L., Cecchi, L. G., & Zucali, P. A. (2024) · European Urology · doi:10.1016/j.eururo.2024.10.004 · Cited by 1
Raad, S., Winzer, R., Apolle, R., Brogsitter, C., Pretze, M., Bundschuh, R. A., Miederer, M., & Hoberück, S. (2025) · Research Square · doi:10.21203/rs.3.rs-7104397/v1 · Cited by 1
SUV harmonization in the era of advanced PET: a necessary recalibration
Piai, A., Pini, C., Vecchio, A. D., & Chiti, A. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100016 · Cited by 1
Galgano, S. J., & Turner, E. M. (2026) · Radiology · doi:10.1148/radiol.260836 · Cited by 1
Sequenztherapie des kastrationsresistenten Prostatakarzinoms
Horak, J., & Omlin, A. G. (2024) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-024-0719-6
177Lu-PSMA-617 extends progression-free survival in taxane-naive mCRPC
Masone, M. C. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00970-z
Diagnostik und Therapie mit PSMA-Liganden
Klaeser, B. (2025) · Urologie in der Praxis · doi:10.1007/s41973-025-00291-7
Zhao, Y., Wang, N., Zhang, Z., & Zhao, X. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2466673
Metadata
- Authors
- Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., Mahammedi, H., Roubaud, G., Študentová, H., Nagarajah, J., Mellado, B., Montesa-Pino, Á., Kpamegan, E., Ghebremariam, S., Kreisl, T. N., Wilke, C., Lehnhoff, K., Sartor, O., & Fizazi, K.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Research Institute Hospital 12 de Octubre (ES)
- National Center for Tumor Diseases (DE)
- Carolina Urologic Research Center (US)
- BC Cancer Agency (CA)
- Institut Català d'Oncologia (ES)
- Centre Léon Bérard (FR)
- Dana-Farber Cancer Institute (US)
- Centre Jean Perrin (FR)
- Institut Bergonié (FR)
- University Hospital Olomouc (CZ)
- Radboud University Medical Center (NL)
- Hospital Clínic de Barcelona (ES)
- Novartis (Switzerland) (CH)
- Mayo Clinic (US)
- Université Paris-Saclay (FR)
- Corresponding author
- Morris, Michael J
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-09
- Volume
- 404
- Issue
- 10459
- Pages
- 1227-1239
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC12121614
- OpenAlex
- W4402552580
- Cited by
- 362
- References
- 47
- Citations by year
- 2026: 204 · 2025: 150 · 2024: 8
- FWCI
- 104.54
- Type
- journal article
- Language
- en
- Update notices
- erratum (2024-12-21)
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Novartis
- National Institutes of Health
- National Cancer Institute (P30 CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- 177Lu-PSMA-617, androgen receptor pathway inhibitors, abiraterone, enzalutamide, radiographic progression-free survival, radiographic progression, overall survival, radioligand therapy
- MeSH terms
- Progression-Free Survival, Aged, Androstenes, Benzamides, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Male, Middle Aged, Nitriles, Phenylthiohydantoin, Radioisotopes, Prostate-Specific Antigen, Taxoids, Androgen Receptor Antagonists, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
